News & Events about Sarepta Therapeutics Inc.
Sumitomo Mitsui Financial Group initiated coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT Get Rating) in a research report sent to investors on Wednesday morning, Briefing.com reports. The firm issued an outperform rating and a $185.00 price target on the biotechnology company...
NEW YORK, April 17, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fox Corporation (NASDAQ: FOX, FOXA), Charles River Laboratories International, Inc. (NYSE: CRL), Provident Bancorp, Inc. (NASDAQ: ...
ATLANTA, April 14, 2023 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Sarepta Therapeutics, Inc. (Sarepta Therapeuticsor the Company) (NASDAQ: SRPT) complied with federal securities laws. On March 16, 2023, Sarepta Therapeutics announced that at its late cycle meeting for the SRP...
Business Wire
2 months ago
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the date of the U.S. Food and Drug Administrations Cellular, Tissue and Gene Therapies Advisory Committee meeting for the SRP-9001 (delandistrogene moxeparvovec) biologics...